Wonderful news for Glioblastoma patients; 2nd clinical trails is underway for the two drug combination that researchers are using to disrupt the cellular process cancer cells use to hide from the immune system and allow the immune system to recognize and attack the cancer.
The UNM Comprehensive Cancer Center has started phase 2 clinical trials, targeting glioblastoma patients.
Glioblastoma is a particularly aggressive type of brain cancer. Only about one fifth of adults diagnosed with it survive two years or more after their diagnosis, UNM researchers said.
“Unfortunately, it is also the most common form of primary brain tumor, about 70 percent of newly diagnosed primary brain tumors,” Omar Chohan, director of Neurosurgical Oncology and a part of the clinical trials team said.
A new two-drug combination, currently in use in the clinical trials, might help people diagnosed with glioblastoma to fight the disease, according to a UNM Comprehensive Cancer Center press release.
Comments are closed.